Index,Sample_id,response_label,RECIST,Timing,cohort,cancer_type,sequencer,ICI,ICI_target,Tissue,Immune phenotype,TMB (FMOne mutation burden per MB),os,censOS,Neoantigen burden per MB,binaryResponse,Sex,Race,Intravesical BCG administered,Baseline ECOG Score,Tobacco Use History,Met Disease Status,Received platinum,Sample collected pre-platinum,sizeFactor,ANONPT_ID,Lund,Lund2,TCGA Subtype,TMB,TMB.interpretation,patient_id,gender,race,ethnicity,age,smoking status,histology,t.stage.at.diagnosis,n.stage.at.diagnosis,d.stage.at.diagnosis,pack.years,os (days),alive,io.lot,ecog,met.lung.cumul,met.liver.cumul,met.bone.cumul,met.other.cumul,fgfr.mutation.yn,duration.of.io.tx,pfs,progressed,geo,alive_status,pfs (days),Gender,"Alive (Y=1, No=0)",Institution,Primary_tumor,Prior_CTLA4,Therapy,Histology,Age,Clinical_Driver,PFS_Event,PFS_Days,OS_Event,OS_Days,loco_prob,Tissue_map,Freeman_response,Overall_survival,Patient,log2_tmb.dan,log2_tmb.wang,RECIST_orignal,Progression Free Survival (Days),Progressed,rnaseq_id,Anatomical Location,Patient ID,Study site,Disease Status,Overall Survival,Vital Status,Previous MAPKi,BRAF,NRAS,NF1,SRA,total_muts,total_neoantigens,CNA_prop,"gender (Male=1, Female=0)",PFS,OS,dead,IOTherapy,BR,RECIST_Response,Mutational Subtype,participant,ICI_target_map,ICI_map,Biopsy_site,sub_cohort,sub_cohort_used_flag,real_TMB
NSCLC_Ravi_SU2CLC-COL-1001-T1,SU2CLC-COL-1001-T1,NR,SD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,138.0,,SU2CLC-COL-1001,,,,,,,,,,,,,,,,,,,,,,,,,,M,,Columbia University,,,,Adeno,70,KRAS,1.0,169.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-COL-1008-T1,SU2CLC-COL-1008-T1,NR,SD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,,,SU2CLC-COL-1008,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Columbia University,,,,Adeno,59,KRAS,1.0,134.0,1.0,237.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-COL-1017-T1,SU2CLC-COL-1017-T1,R,PR,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,,,SU2CLC-COL-1017,,,,,,,,,,,,,,,,,,,,,,,,,,M,,Columbia University,,,,Adeno,67,,0.0,225.0,0.0,225.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-COL-1020-T1,SU2CLC-COL-1020-T1,NR,SD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,,,SU2CLC-COL-1020,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Columbia University,,,,Adeno,51,,1.0,87.0,1.0,364.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-COL-1021-T1,SU2CLC-COL-1021-T1,NR,PD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,,,SU2CLC-COL-1021,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Columbia University,,,,Adeno,78,,1.0,72.0,1.0,181.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-COL-1023-T1,SU2CLC-COL-1023-T1,NR,SD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,,,SU2CLC-COL-1023,,,,,,,,,,,,,,,,,,,,,,,,,,M,,Columbia University,,,,Adeno,47,,1.0,106.0,0.0,197.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-COL-1026-T1,SU2CLC-COL-1026-T1,NR,PD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,,,SU2CLC-COL-1026,,,,,,,,,,,,,,,,,,,,,,,,,,M,,Columbia University,,,,Adeno,67,BRAF,1.0,89.0,1.0,285.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-COL-1031-T1,SU2CLC-COL-1031-T1,NR,SD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,240.0,,SU2CLC-COL-1031,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Columbia University,,,,Adeno,69,,1.0,91.0,1.0,190.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-COL-1032-T1,SU2CLC-COL-1032-T1,NR,SD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,,,SU2CLC-COL-1032,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Columbia University,,,,Adeno,55,KRAS,1.0,68.0,0.0,388.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-COL-1034-T1,SU2CLC-COL-1034-T1,NR,SD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,769.0,,SU2CLC-COL-1034,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Columbia University,,,,Adeno,70,KRAS,0.0,232.0,0.0,232.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-COL-1036-T1,SU2CLC-COL-1036-T1,R,CR,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,,,SU2CLC-COL-1036,,,,,,,,,,,,,,,,,,,,,,,,,,M,,Columbia University,,,,Adeno,49,,0.0,384.0,0.0,384.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-COL-1037-T1,SU2CLC-COL-1037-T1,R,PR,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,257.0,,SU2CLC-COL-1037,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Columbia University,,,,Adeno,55,,0.0,478.0,0.0,478.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-COL-1041-T1,SU2CLC-COL-1041-T1,NR,SD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,,,SU2CLC-COL-1041,,,,,,,,,,,,,,,,,,,,,,,,,,M,,Columbia University,,,,Adeno,73,,1.0,311.0,1.0,575.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-COL-1044-T1,SU2CLC-COL-1044-T1,NR,PD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,,,SU2CLC-COL-1044,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Columbia University,,,,Adeno,77,,1.0,56.0,0.0,138.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-DFC-1536-T1,SU2CLC-DFC-1536-T1,R,PR,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,428.0,,SU2CLC-DFC-1536,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Dana-Farber Cancer Institute,,,,Adeno,70,KRAS,1.0,331.0,1.0,392.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-DFC-1537-T1,SU2CLC-DFC-1537-T1,R,PR,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,,,SU2CLC-DFC-1537,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Dana-Farber Cancer Institute,,,,Adeno,62,KRAS,0.0,483.0,0.0,483.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-DFC-1538-T1,SU2CLC-DFC-1538-T1,NR,PD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,,,SU2CLC-DFC-1538,,,,,,,,,,,,,,,,,,,,,,,,,,M,,Dana-Farber Cancer Institute,,,,Adeno,61,,1.0,56.0,1.0,67.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-DFC-DF0499-T1,SU2CLC-DFC-DF0499-T1,NR,SD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,123.0,,SU2CLC-DFC-DF0499,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Dana-Farber Cancer Institute,,,,Adeno,47,ALK,1.0,132.0,1.0,301.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-DFC-DF0510-T1,SU2CLC-DFC-DF0510-T1,NR,SD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,150.0,,SU2CLC-DFC-DF0510,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Dana-Farber Cancer Institute,,,,Adeno,52,BRAF,1.0,127.0,1.0,449.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-DFC-DF0512-T1,SU2CLC-DFC-DF0512-T1,NR,SD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,,,SU2CLC-DFC-DF0512,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Dana-Farber Cancer Institute,,,,Adeno,73,KRAS,0.0,464.0,0.0,464.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-DFC-DF0668-T1,SU2CLC-DFC-DF0668-T1,NR,PD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,2238.0,,SU2CLC-DFC-DF0668,,,,,,,,,,,,,,,,,,,,,,,,,,M,,Dana-Farber Cancer Institute,,,,Adeno,74,,1.0,37.0,1.0,124.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-DFC-DF0840-T1,SU2CLC-DFC-DF0840-T1,NR,PD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,526.0,,SU2CLC-DFC-DF0840,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Dana-Farber Cancer Institute,,,,Adeno,54,KRAS,1.0,84.0,0.0,271.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-MDA-1561-T1,SU2CLC-MDA-1561-T1,NR,PD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,,,SU2CLC-MDA-1561,,,,,,,,,,,,,,,,,,,,,,,,,,M,,MD Anderson,,,,Adeno,47,,1.0,43.0,0.0,51.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-MDA-1562-T1,SU2CLC-MDA-1562-T1,NR,PD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,,,SU2CLC-MDA-1562,,,,,,,,,,,,,,,,,,,,,,,,,,M,,MD Anderson,,,,Adeno,64,KRAS,1.0,47.0,1.0,235.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-MGH-1161-T2,SU2CLC-MGH-1161-T2,R,CR,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,191.0,,SU2CLC-MGH-1161,,,,,,,,,,,,,,,,,,,,,,,,,,M,,Massachusetts General Hospital,,,,Adeno,73,NF1,0.0,79.0,0.0,361.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-MGH-1412-T1,SU2CLC-MGH-1412-T1,R,PR,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,1282.0,,SU2CLC-MGH-1412,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Massachusetts General Hospital,,,,Adeno,75,KRAS,1.0,298.0,1.0,298.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-MGH-1415-T1,SU2CLC-MGH-1415-T1,R,CR,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,672.0,,SU2CLC-MGH-1415,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Massachusetts General Hospital,,,,Adeno,70,"KRAS, BRCA2",0.0,286.0,0.0,286.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-MGH-1490-T1,SU2CLC-MGH-1490-T1,R,PR,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,426.0,,SU2CLC-MGH-1490,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Massachusetts General Hospital,,,,Adeno,52,"KRAS, KEAP1",1.0,221.0,1.0,270.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-MGH-1493-T1,SU2CLC-MGH-1493-T1,NR,SD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,,,SU2CLC-MGH-1493,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Massachusetts General Hospital,,,,Adeno,64,"BRCA1, CDK4",0.0,22.0,0.0,139.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-MGH-1568-T1,SU2CLC-MGH-1568-T1,NR,PD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,218.0,,SU2CLC-MGH-1568,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Massachusetts General Hospital,,,,Adeno,68,TP53,1.0,43.0,0.0,188.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-MGH-1574-T1,SU2CLC-MGH-1574-T1,R,PR,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,,,SU2CLC-MGH-1574,,,,,,,,,,,,,,,,,,,,,,,,,,M,,Massachusetts General Hospital,,,,Adeno,68,TP53,0.0,609.0,0.0,609.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-MGH-1575-T1,SU2CLC-MGH-1575-T1,NR,PD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,344.0,,SU2CLC-MGH-1575,,,,,,,,,,,,,,,,,,,,,,,,,,F,,Massachusetts General Hospital,,,,Adeno,62,"KRAS, TP53, STK11",1.0,52.0,1.0,99.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
NSCLC_Ravi_SU2CLC-MSK-1365-T1,SU2CLC-MSK-1365-T1,NR,SD,Pre,SU2CLC1,LUAD,HiSeq2500,Pembrolizumab,PD1,,,,,,,,,,,,,,,,,,,,,67.0,,SU2CLC-MSK-1365,,,,,,,,,,,,,,,,,,,,,,,,,,M,,Memorial Sloan Kettering,,,,Adeno,73,KRAS,0.0,400.0,0.0,436.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PD1,Pembro,,SU2CLC1(Pembro),True,
